ACC Gene Therapy Targeting MOR Mimicked Morphine for Chronic Pain in Mice

TL;DR: A 2026 Nature mouse study isolated an anterior-cingulate pain-unpleasantness circuit that morphine calms, then mimicked that relief with MORp-driven chemogenetic inhibition in nerve-injured mice.

Source: Nature (2026) | Oswell et al.

The central problem in opioid analgesia is selectivity. Drugs such as morphine can reduce pain suffering, but they also act across circuits involved in breathing, reward, gut motility, tolerance, and dependence.

This study asked a surgical question: What if you could isolate the exact cortical pain circuit opioids calm down, then turn off only that circuit on demand?

Anterior Cingulate Cortex Mu-Opioid Receptors Tracked Pain Unpleasantness

One of the most important ideas in pain neuroscience is that pain intensity and pain unpleasantness are not the same thing. You can feel a stimulus and still suffer less from it — which is why cingulotomy once helped some patients with intractable pain without making them numb to every harmful sensation.

This paper builds on that idea. The target was the anterior cingulate cortex, especially a 700-µm pain-responsive hotspot where the authors found neurons expressing the mu-opioid receptor — the same receptor morphine binds. The team was not looking for a vague “pain area.” They were looking for the cortical ensemble most plausibly responsible for the part of pain opioids actually soften.

Modern analgesic development has spent decades chasing molecules more than circuits. If the emotionally aversive part of chronic pain lives in a defined cortical network, a therapy aimed at that network could keep the benefit while shedding much of opioids’ systemic baggage.

How LUPE Turned Mouse Behavior Into an Affective Pain Score

Standard rodent pain assays lean on reflexes — paw withdrawal under a mechanical or thermal stimulus. Useful but crude. They tell you whether an animal reacts, not whether it is trapped in an ongoing aversive state that resembles human chronic pain.

The team built a tracking platform called LUPE that followed 20 body points in freely moving mice, classified six broad behaviors, and used transition patterns among them to infer latent pain states. In acute formalin and capsaicin experiments with 20 mice per condition, the system extracted a principal-component measure the authors call the affective-motivational pain scale (AMPS).

Morphine did not just flatten everything. It selectively suppressed the dimension that rose with injury and tracked affective pain. That is the paper’s first real innovation. If your pain scale cannot distinguish sensory detection from pain burden, you cannot really claim to have built a safer analgesic.

The Receptor Logic That Made the Mechanism Specific

The most convincing causal experiment was not the gene therapy. It was the receptor logic.

When the authors deleted mu-opioid receptors specifically from anterior cingulate neurons, 0.5 mg/kg morphine no longer reduced affective-motivational pain responses. Re-expressing those receptors in the same cortical region of global knockout mice brought the analgesic effect back.

The sequence narrows the mechanism dramatically. The paper is not just saying the ACC lights up during pain or quiets after opioids. Morphine’s relief of pain unpleasantness depended on opioid receptor action inside that cortical ensemble: removing the receptors erased the effect, and restoring them brought it back.

Single-nucleus RNA sequencing added another layer. In the nociceptive hotspot, 23 cell types resolved — but only three glutamatergic clusters showed persistent nociceptive and neuropathic immediate-early-gene signatures, and all three expressed Oprm1. The pain-relevant cells and the opioid-relevant cells were the same cells.

The implication: opioids may work less by muting raw sensory input than by quieting a cortical network that tags pain as urgent, aversive, and behaviorally compelling. That is exactly the component drug developers would love to separate from respiratory depression and reward effects.

Live Circuit Dynamics Confirmed the Circuit Behavior

The paper then moved from cell identity to live circuit dynamics. In 5 mice carrying calcium indicators and GRIN lenses, the authors recorded ACC activity during acute capsaicin pain and morphine analgesia inside the LUPE chamber.

They identified “Plick” neurons — cells whose activity predicted the probability of pain-related licking. These were not random bystanders. Their activity changed with injury, changed with morphine, and predicted how much time the animal spent in pain-linked states.

By 3 weeks after spared nerve injury, the lick-linked neural responses were blunted, and morphine partially restored them. Chronic pain in this model was not simply more firing — it was a reorganization of the behavioral-neural relationship inside the anterior cingulate. Morphine appeared to rescue that relationship, which fits the larger claim that opioid analgesia changes the affective computation of pain rather than just numbing input.

The Gene Therapy That Mimicked Morphine

Once the team knew which cortical ensemble morphine was calming, they tried to mimic the effect without morphine. The tool was a synthetic mu-opioid receptor promoter (MORp) designed to drive expression selectively in opioid-sensitive ACC neurons. Into those cells, they delivered an inhibitory chemogenetic construct, hM4Di, activatable with deschloroclozapine.

The logic is elegant. Instead of delivering an opioid systemically and hoping the right cells are hit among many wrong ones, deliver a genetic actuator only to the right cells — then turn those cells down on command. In neuropathic pain experiments, the MORp-hM4Di approach moved three readouts:

• Injured-paw licking: less time showing spontaneous pain-linked behavior.
• Pain-state occupancy: LUPE classified less time in latent pain states.
• AMPS score: the affective-motivational pain scale moved downward.

The morphine comparison is where the paper gets ambitious. The gene-therapy strategy matched morphine on affective pain relief and outperformed it on some heat and cold assays in injured mice.

Mechanical von Frey thresholds did not change — consistent with the thesis that the intervention is best at unpleasant, motivational pain, not universal sensory shutdown. Brain-wide imaging also showed the chemogenetic inhibition calmed downstream activity, so the therapy was not just changing one local signal but quieting a broader pain network through one strategic cortical entry point.

ACC Circuit Silencing Was Rewarding Only in Nerve-Injured Mice

The addiction question hangs over every opioid-adjacent paper. The most reassuring result is the place-preference assay.

Silencing these ACC MOR-positive neurons was reinforcing in mice with nerve injury — what you would expect if the intervention relieved ongoing suffering. The same manipulation did not create place preference in uninjured mice.

That is not proof of an addiction-proof approach. It is a mouse assay, not a human safety dossier.

But state dependence matters. A treatment that feels rewarding only when pain is present is fundamentally different from a drug that becomes rewarding in healthy tissue too.

The translational leap is enormous. This is preclinical mouse work using viral tools, invasive access, and synthetic promoter engineering. The authors point toward future noninvasive delivery ideas — focused ultrasound BBB opening — but that is forward-facing speculation, not next year’s clinic plan.

The right way to read the paper is not “gene therapy cures chronic pain.” It is narrower and more useful: opioid analgesia can be reverse-engineered at the circuit level. If the suffering component of chronic pain depends on a defined anterior cingulate ensemble, safer analgesics may come from targeting that ensemble directly — rather than flooding the whole body with opioid molecules.